Overview

Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)

Status:
NOT_YET_RECRUITING

Trial end date:
2027-01-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to assess the PK/PD relationship of nemolizumab in adult participants aged 18 years or above with chronic pruritus of unknown origin (CPUO) during a 16-week treatment period.

Phase:

PHASE2

Details

Lead Sponsor:

Galderma R&D

Treatments:

nemolizumab